about
Reactivity and mutagenicity of endogenous DNA oxopropenylating agents: base propenals, malondialdehyde, and N(epsilon)-oxopropenyllysine.The impact of stool and gas volume on intrafraction prostate motion in patients undergoing radiotherapy with daily endorectal balloon.Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde.Endogenous DNA damage and mutation.Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report.The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia.Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopurinone adduct of deoxyguanosine by base propenalImproved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee.ACR appropriateness criteria follow-up of Hodgkin lymphoma.Gastrointestinal cancer: nonliver proton therapy for gastrointestinal cancers.Special cases for proton beam radiotherapy: re-irradiation, lymphoma, and breast cancer.Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment.Radiation Oncology Resident In-Training Examination.Proton pencil beam scanning for mediastinal lymphoma: the impact of interplay between target motion and beam scanning.Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer.ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas.Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States.A one, two punch for liver cancer: anti-angiogenesis with a death receptor agonist.A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer.Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.Diffusely metastatic digital papillary adenocarcinoma 11 years after initial presentation treated with palliative chemotherapy and radiotherapy.A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma.Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer.Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.Omission of adjuvant therapy after gastric cancer resection: development of a validated risk model.Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy.Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma.The case for combined-modality therapy for limited-stage Hodgkin's disease.
P50
Q31729641-83A2830B-B7A5-43D7-890D-6CC578B96E16Q33462253-7C278B01-6ACC-483B-8186-5624F80A933AQ33766529-8DCE6713-16F3-4DD7-83A5-97972330F6C2Q33898260-8F800CC6-C853-437F-BCAE-2528E3C27144Q34199014-303A5B1D-4EDD-41D1-B455-B0B5529F615FQ34418908-1225BFA8-3A82-42D4-8AE4-430265D90F52Q35032285-5E752043-071A-4624-9BDA-43216390A073Q35235334-5B42DEB1-85C2-4BF5-826C-10CD5E271AEEQ36307311-C0D8CCA0-CB4D-4CA6-A09F-A10B431BA259Q37613287-E0FFC50E-0131-4F83-AAE1-8A0244E5247BQ37992341-62488F8E-C230-42C0-A505-F269AE6DEAB8Q38256324-4190043E-AE8A-4EB9-B31B-F7C1AF137952Q38270341-86631DF5-3FB6-4D84-B15A-C9EC153B7931Q38286855-8BB0AB80-50C3-4EE5-A83D-15330DB4CEEAQ38407140-B8E55068-DD3A-4FB1-A7D7-D1C4C77E3EFAQ38413357-B4F42E0C-B425-410F-BD4F-24AAF8EDF493Q38415741-72625447-8AA9-4B54-AF9C-B2C40A4C0E26Q38447748-6E225241-2A49-4A50-A1ED-19C970F04A39Q38638303-395E31F8-AA94-4AFA-A57C-5C0CEEEA6898Q38688815-A4FF8B9D-47DF-425C-87B8-D1BC0238590AQ38864735-F11D34E3-FF43-427D-8212-AFFF278EC7C4Q39149609-0167391F-A159-4FBD-A518-14FA2FAFE323Q39765503-F80452EF-2C34-4F18-95F7-1A77A49B5F3EQ39841938-3000DD63-6643-4DF8-9846-7FFCB3BA90B8Q39874565-2738D954-2434-47E0-9D8E-4E4F0D79651CQ40021666-10CDB48C-9B56-4BFC-BA1C-8AD3D261AE81Q40050247-0B6B46C0-9371-4CBD-AC5C-FA20038C473DQ40110911-B21271E6-4912-4D84-BEB0-A52E8718CB0AQ40119782-57D16813-4DA0-44C5-9034-6D0036161120Q40139318-78C2997E-962F-45E3-BAFA-33DEE658917BQ40195388-B13814D1-BAFA-4E9A-A18A-C4AFD1E4CEA7Q40421108-20DD38F5-3818-48CA-B6EF-7E3A7D58981EQ40483350-7F687F29-92F3-42A8-978F-0AFA50F9303CQ40575600-154F168B-0B71-4301-80A6-7EBB67849D97Q40670901-ED4F156F-0782-4F81-B8E6-C1640E1E6208Q40775168-8F1081B0-EB90-44C3-8C18-5F7A530D0BDDQ40949443-222B4908-CCB8-4843-8880-44D398D1C008Q41312134-EEDA7855-BFEA-4E48-82D2-A31725FEFA98Q41598639-4A320BBF-2BF6-44AF-A93A-80EE980FFEF1Q43246318-616D1FA3-4990-4A29-84DA-9FA8EEBC99B8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John P Plastaras
@ast
John P Plastaras
@en
John P Plastaras
@es
John P Plastaras
@nl
John P Plastaras
@sl
type
label
John P Plastaras
@ast
John P Plastaras
@en
John P Plastaras
@es
John P Plastaras
@nl
John P Plastaras
@sl
prefLabel
John P Plastaras
@ast
John P Plastaras
@en
John P Plastaras
@es
John P Plastaras
@nl
John P Plastaras
@sl
P106
P21
P31
P496
0000-0002-4916-9857